SYBX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Stats
Today's Volume	7 120.00
Average Volume	51 129.00
Market Cap	20.81M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.820 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.200
ATR14	$0.0230 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Dooley Mary Beth	Sell	188	Common Stock
2024-04-02	Awad Antoine	Sell	372	Common Stock
2024-03-18	Dooley Mary Beth	Sell	0	Common Stock
2024-03-18	Dooley Mary Beth	Sell	3 612	Stock Option (right to buy)
2024-03-19	Flynn James P	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
-63.68
Last 97 transactions
Buy: 6 126 214 \| Sell: 2 856 834

Synlogic Inc Correlation

10 Most Positive Correlations
SJ	0.953
PRSO	0.947
SGML	0.945
DCOM	0.941
EXTR	0.94
MATW	0.939
HAFC	0.938
SHBI	0.936
KRNY	0.932
CHTR	0.931

10 Most Negative Correlations
ATCX	-0.937
IIN	-0.927
MOR	-0.924
META	-0.921
TESS	-0.919
TA	-0.918
ECHO	-0.91
SGIIU	-0.909
TACO	-0.909
LIBY	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Synlogic Inc Financials

Annual	2023
Revenue:	$3.37M
Gross Profit:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2023
Revenue:	$3.37M
Gross Profit:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2022
Revenue:	$1.18M
Gross Profit:	$-4.49M (-380.42 %)
EPS:	$-13.57

FY	2021
Revenue:	$1.75M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.090

Financial Reports:

No articles found.

Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.